The issued US patent extends the intellectual property surrounding the company’s franchise of oral gallium-containing products that are intended as potential treatment for diseases associated with accelerated bone
Luvox CR was recently approved by the FDA for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD) in adult patients. SAD and OCD are
The supplemental new drug application (sNDA) is based on results from a recent study comparing patients who received Risperdal Consta and standard treatment to those who received standard
The interim analysis of 806 patients who completed three months in the study showed dose-related, statistically significant reductions in A1c. The mean changes for patients in the 150mg,
Under the terms of the agreement, Debiopharm will pay Airmid an option fee for signature of the contract. If Debiopharm exercises its exclusive option to license-in the product
Under the terms of the agreement, Rib-X and the Molecular Biology of the Medical Research Council (MRC) will continue to jointly explore the high resolution crystal structure of
This is a single center, randomized, single masked, comparative-group safety and tolerability study of a range of single iontophoretic dose levels with a citrate buffer via the EyeGate
The trial (REO 011) has two components. The first is an open-label, dose-escalating, non-randomized study of Reolysin given intravenously with paclitaxel and carboplatin every three weeks. Standard dosages
The study, conducted in mouse models of oral mucositis, showed that NU206 (R-spondin1) regenerated basal layer epithelial cells and accelerated cell repair by stimulating the Wnt pathway, a
The Buck Institute and Q Therapeutics will use their expertise in differentiating stem cells to provide key cell types needed to study Parkinson’s disease. These neural-lineage cell lines
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.